A Study to Learn How Safe the Study Drug Finerenone is and How Well it Works in Indian People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 2 Diabetes Mellitus
NCT ID: NCT05705271
Last Updated: 2025-07-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
200 participants
INTERVENTIONAL
2023-02-08
2025-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In people with T2D, the body does not make enough of a hormone called insulin or does not use the insulin well enough. Insulin's role is to regulate the amount of glucose (sugar) in the blood. Too much blood sugar can cause damage to the kidneys over time. Consequently, CKD can happen as one of the complications of T2D.
The study treatment finerenone works by blocking a group of proteins, called mineralocorticoid receptor. An increased stimulation of the mineralocorticoid receptor is known to trigger injury and inflammation in the kidney and is therefore thought to play a role in CKD.
Finerenone is already available in several countries for doctors to prescribe to people with CKD and T2D. In addition, it was recently approved in India with a request to specifically gather information on finerenone therapy in Indians.
The main purpose of this study is to learn how safe finerenone is in Indian people with CKD and T2D. For this, the researchers will count the number of participants who have:
* medical problems after taking finerenone
* abnormal high levels of potassium in the blood (called hyperkalemia).
Researcher will also count the number of participants in whom hyperkalemia:
* leads to stop of finerenone treatment
* requires treatment to filter wastes and water from the blood
* leads to a hospital stay.
Doctors keep track of all medical problems that happen in studies, even if they do not think the medical problems might be related to the study treatments.
In addition, the study team will collect more data about how well finerenone works in Indian people with CKD and T2D under real world setting. Working well means that the treatment can prevent the following from happening:
* reduced kidney function over a period of at least 4 weeks
* death from renal problems
* death due to conditions affecting the heart and blood circulation
* heart attack (blocked blood flow to the heart)
* hospital stay due to a condition which occurs when the heart does not pump blood as well as it should
* changes of the albumin and creatinine levels in urine.
The participants will be in the study for approximately 20 months. They will take the study treatment once daily as a tablet by mouth for 18 months. In the study, 9 visits to the study site are planned.
During the study, the study team will:
* take blood and urine samples
* do physical examinations
* check the participants' overall health
* do pregnancy tests
* examine heart health using electrocardiogram ECG
* check vital signs.
About 30 days after the participants take their last treatment, the study doctors and their team will check worsening of reported underlying diseases:
* damage to the blood vessels in the tissue of the retina at the back of the eye, as a result of diabetes mellitus
* a long-term condition where the heart does not pump blood as well as it should with symptoms such as shortness of breath, tiredness and ankle swelling
* heart attack (blocked blood flow to the heart)
* death due to conditions affecting the heart and blood circulation or
* hospital stay.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in Indian People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Practice
NCT06763146
An Observational Study to Learn More About How Safe Finerenone is and How Well it Works in People With Chronic Kidney Disease and Type 2 Diabetes in Routine Medical Care in the United States
NCT06608212
An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
NCT06278207
An Observational Study Called FIRST-2.0 to Learn More About the Use of the Study Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
NCT05703880
A Study to Learn How Well the Study Treatment Finerenone Works and How Safe it is in People With Long-term Decrease in the Kidneys' Ability to Work Properly (Chronic Kidney Disease) Together With Type 1 Diabetes
NCT05901831
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Finerenone
Participants will receive study treatment for 18 months ± 7 days.
Finerenone (Kerendia, BAY94-8862)
Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Finerenone (Kerendia, BAY94-8862)
Film-coated tablet, oral administration, once daily (OD), dosage based on the eGFR and serum potassium thresholds
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of chronic kidney disease (CKD) associated with type 2 diabetes (T2D).
* Participants who are drug naïve for finerenone or patients who have been initiated on finerenone therapy within 4 weeks before signing the informed consent.
* Participants with serum potassium level ≤ 4.8 mmol/L at the time of Screening. If serum potassium level \> 4.8 to 5.0 mmol/L, participants may be enrolled in the study, but additional potassium samples may be required; the potassium level needs to be confirmed during Screening. Participants with potassium level \> 5.0 mmol/L are not allowed. The sample for potassium assessment for confirming eligibility shall be available before initiation of treatment with finerenone.
* Contraceptive use by women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
Exclusion Criteria
1. Participants with eGFR \< 25 mL/min/1.73 m\^2 (calculated based on the CKD-EPI equation, using 2009 formula). eGFR can be reassessed once within 48 hours.
2. Participants with severe hepatic impairment (Child-Pugh C).
3. Participants with known hypersensitivity to the study treatment (active substance or excipients).
4. Participants with Type 1 Diabetes.
5. Participants taking concomitant medications that are strong CYP3A4 inhibitors.
6. Participants with Addison's disease.
* Glycated hemoglobin \> 12% (17.5 mmol/L) at the Screening visit.
* Participants treated with another mineralocorticoid receptor antagonist (MRA), a renin inhibitor, potassium supplements, a potassium sparing diuretic, a potassium binder agent, or angiotensin receptor neprilysin inhibitor (ARNI) within 8 weeks prior to the Screening visit and during finerenone treatment.
* Participation in another interventional clinical trial within 30 days prior to the Screening visit and during finerenone treatment.
* Female participants who are pregnant or breast-feeding or plan to become pregnant or to breastfeed during the course of the study.
* Participants known for lack of compliance with clinic visits or prescribed medication.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bayer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bhate Hospital
Karnataka, Belagavi, India
Muljibhai Patel Urological Hospital (MPUH) (Kidney Hospital)
Nadiād, Gujarat, India
Accord Superspeciality Hospital
Faridabad, Haryana, India
Kempegowda Institute of Medical Sciences Hospital & R C
Bangalore, Karnataka, India
Christian Medical College
Vellore, Kerala, India
Global Hospital-Super Speciality And Transplant Centre
Mumbai, Maharashtra, India
Lancelot Medical Centre
Mumbai, Maharashtra, India
Dr Balabhai Nanavati Hospital
Mumbai, Maharashtra,, Maharashtra, India
PSRI Institute of Renal Sciences
New Delhi, National Capital Territory of Delhi, India
Vardhman Mahavir Medical College & Safdarjung Hospital (VMMC-SJH)
New Delhi, National Capital Territory of Delhi, India
All India Institute of Medical Sciences
Bhubaneswar, Odisha, India
Jawaharlal Institute Of Postgraduate Medical Education and R
Gorimedu, Puducherry, India
Government Stanley Medical College and Hospital
Chennai, Tamil Nadu, India
M.V. Hospital & Research Centre 314/30
Chowk Lucknow, Uttar Pradesh, India
Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS)
Lucknow, Uttar Pradesh, India
Medica Superspecialty Hospital
Kolkata, West Bengal, India
Nizam's Institute of Medical Sciences (NIMS)
Hyderabad, , India
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Click here to find information for studies related to Bayer products. To find this study enter the ClinicalTrials.gov identifier (NCT) number or Bayer Study Identifier (ID) in the search field.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
22224
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.